This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Done, M. J. Articles by Brown, J. M. Search for Related Content PubMed PubMed Citation Articles by Done, M. J. Articles by Brown, J. M.

Tumor-specific, Schedule-dependent Interaction between Tirapazamine (SR 4233) and Cisplatin¹

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305-5468

² To whom requests for reprints should be addressed, at Division of Radiation Biology, CBRL, GK103, Department of Radiation Oncology, Stanford Medical Center, Stanford, CA 94305-5468.

Tirapazamine (SR 4233), a benzotriazine di-N-oxide, a potent and selective killer of hypoxic cells, is currently in Phase I clinical trials with the expectation that it will be combined with radiation therapy. However, because of the likelihood that hypoxic tumor cells may also be resistant to some commonly used chemotherapeutic agents, we have tested tirapazamine in combination with cisplatin (c-DDP) in the mouse RIF-1 tumor. A large, schedule-dependent enhancement of tumor cell killing was observed both in vivo and in vitro, with a maximal response observed when the SR 4233 was given 2-3 h before c-DDP. Assay of serum blood urea nitrogen levels following treatment with these two drugs indicates that SR 4233 does not enhance the kidney damage which can result from high doses of c-DDP. Leukopenia induced by the two drugs in combination was equal to that predicted from an additive effect of the responses to the individual drugs. Also, there was no change in the systemic toxicity of c-DDP (as judged by 50% lethal dose) when SR 4233 was combined with c-DDP at a dose and timing that produced the maximum tumor interaction. These observations point to a promising new combination therapy with considerable therapeutic advantage.

¹ Supported by USPHS Grant CA 15201 and by Sterling Drug, Inc.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 5/21/93. Accepted 7/28/93.

This article has been cited by other articles:

				W. R. Wilson, S. M. Stribbling, F. B. Pruijn, S. P. Syddall, A. V. Patterson, H.D. S. Liyanage, E. Smith, K. J. Botting, and M. Tercel Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators Mol. Cancer Ther., October 1, 2009; 8(10): 2903 - 2913. [Abstract] [Full Text] [PDF]

				R L Cowen, E J Garside, B Fitzpatrick, M V Papadopoulou, and K J Williams Gene therapy approaches to enhance bioreductive drug treatment Br. J. Radiol., October 1, 2008; 81(Special_Issue_1): S45 - S56. [Abstract] [Full Text] [PDF]

				K. A. Krohn, J. M. Link, and R. P. Mason Molecular Imaging of Hypoxia J. Nucl. Med., June 1, 2008; 49(Suppl_2): 129S - 148S. [Abstract] [Full Text] [PDF]

				J. W. Evans, S. B. Chernikova, L. A. Kachnic, J. P. Banath, O. Sordet, Y. M. Delahoussaye, A. Treszezamsky, B. H. Chon, Z. Feng, Y. Gu, et al. Homologous Recombination Is the Principal Pathway for the Repair of DNA Damage Induced by Tirapazamine in Mammalian Cells Cancer Res., January 1, 2008; 68(1): 257 - 265. [Abstract] [Full Text] [PDF]

				O. Riesterer, L. Milas, and K. K. Ang Use of Molecular Biomarkers for Predicting the Response to Radiotherapy With or Without Chemotherapy J. Clin. Oncol., September 10, 2007; 25(26): 4075 - 4083. [Abstract] [Full Text] [PDF]

				D. Rischin, R. J. Hicks, R. Fisher, D. Binns, J. Corry, S. Porceddu, and L. J. Peters Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography-Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J. Clin. Oncol., May 1, 2006; 24(13): 2098 - 2104. [Abstract] [Full Text] [PDF]

				S. K. Williamson, J. J. Crowley, P. N. Lara Jr, J. McCoy, D. H.M. Lau, R. W. Tucker, G. M. Mills, and D. R. Gandara Phase III Trial of Paclitaxel Plus Carboplatin With or Without Tirapazamine in Advanced Non-Small-Cell Lung Cancer: Southwest Oncology Group Trial S0003 J. Clin. Oncol., December 20, 2005; 23(36): 9097 - 9104. [Abstract] [Full Text] [PDF]

				D. Rischin, L. Peters, R. Fisher, A. Macann, J. Denham, M. Poulsen, M. Jackson, L. Kenny, M. Penniment, J. Corry, et al. Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02) J. Clin. Oncol., January 1, 2005; 23(1): 79 - 87. [Abstract] [Full Text] [PDF]

				Q.-T. Le, J. McCoy, S. Williamson, J. Ryu, L. E. Gaspar, M. J. Edelman, S. R. Dakhil, S. D. Sides, J. J. Crowley, and D. R. Gandara Phase I Study of Tirapazamine Plus Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer (S0004): A Southwest Oncology Group Study Clin. Cancer Res., August 15, 2004; 10(16): 5418 - 5424. [Abstract] [Full Text] [PDF]

				E. E.W. Cohen, M. W. Lingen, and E. E. Vokes The Expanding Role of Systemic Therapy in Head and Neck Cancer J. Clin. Oncol., May 1, 2004; 22(9): 1743 - 1752. [Abstract] [Full Text] [PDF]

				V. M. Aquino, S. D. Weitman, N. J. Winick, S. Blaney, W. L. Furman, J. L. Kepner, P. Bonate, M. Krailo, W. Qu, and M. Bernstein Phase I Trial of Tirapazamine and Cyclophosphamide in Children With Refractory Solid Tumors: A Pediatric Oncology Group Study J. Clin. Oncol., April 15, 2004; 22(8): 1413 - 1419. [Abstract] [Full Text] [PDF]

				R. L. Cowen, K. J. Williams, E. C. Chinje, M. Jaffar, F. C. D. Sheppard, B. A. Telfer, N. S. Wind, and I. J. Stratford Hypoxia Targeted Gene Therapy to Increase the Efficacy of Tirapazamine as an Adjuvant to Radiotherapy: Reversing Tumor Radioresistance and Effecting Cure Cancer Res., February 15, 2004; 64(4): 1396 - 1402. [Abstract] [Full Text] [PDF]

				R. Airley, J. Loncaster, S. Davidson, M. Bromley, S. Roberts, A. Patterson, R. Hunter, I. Stratford, and C. West Glucose Transporter Glut-1 Expression Correlates with Tumor Hypoxia and Predicts Metastasis-free Survival in Advanced Carcinoma of the Cervix Clin. Cancer Res., April 1, 2001; 7(4): 928 - 934. [Abstract] [Full Text]

				D. Rischin, L. Peters, R. Hicks, P. Hughes, R. Fisher, R. Hart, M. Sexton, I. D'Costa, and R. von Roemeling Phase I Trial of Concurrent Tirapazamine, Cisplatin, and Radiotherapy in Patients With Advanced Head and Neck Cancer J. Clin. Oncol., January 15, 2001; 19(2): 535 - 542. [Abstract] [Full Text] [PDF]

				J. von Pawel, R. von Roemeling, U. Gatzemeier, M. Boyer, L. O. Elisson, P. Clark, D. Talbot, A. Rey, T. W. Butler, V. Hirsh, et al. Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group J. Clin. Oncol., March 13, 2000; 18(6): 1351 - 1359. [Abstract] [Full Text] [PDF]

				J. M. Brown The Hypoxic Cell: A Target for Selective Cancer Therapy--Eighteenth Bruce F. Cain Memorial Award Lecture Cancer Res., December 1, 1999; 59(23): 5863 - 5870. [Abstract] [Full Text] [PDF]